Creatine Kinase MB Isoenzyme (CK-MB)
Heterodimeric creatine kinase isozyme composed of one M and one B subunit (MB), comprising ~20% of total CK in cardiac myocardium.
Standard vs. Optimal Reference Rangesng/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<5.0 ng/mL (or <3.0% CK-MB Relative Index)
General reference distribution across unselected commercial populations.
<2.5 ng/mL
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Released into circulation within 4 to 6 hours of myocardial necrosis, peaking at 18 hours and clearing rapidly within 48 to 72 hours.
Differential Diagnosis
Elevated Levels (CK-MB High)
- •Acute myocardial infarction
- •Acute myocarditis and cardiac trauma
- •Early peri-procedural cardiac re-infarction
Low Levels (CK-MB Low)
- •Intact myocardial sarcomeres
- •Skeletal muscle injury alone (CK-MB Relative Index <2.5%)
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for CK-MB
- Targeted organ system imaging or functional dynamic testing related to myocardial necrosis & relative index
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Creatine Kinase MB Isoenzyme - The New England Journal of Medicine (2021). PMID: 34190124
- [2]CK-MB Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35422901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Creatine Kinase MB Isoenzyme (CK-MB) into overall healthspan optimization.